孤立性快速眼动睡眠行为障碍向α-突触核蛋白病转化的生物标志物
孤立性快速眼动睡眠行为障碍(RBD)患者常被视为α-突触核蛋白病(如帕金森病、路易体痴呆、多系统萎缩)的早期阶段。α-突触核蛋白异常沉积在中枢和外周神经系统早期出现,可能早于运动症状和认知下降数十年。这些发现为开发可靠生物标志物以预测临床转化提供了依据,并强调疾病进展和亚型标志物的重要性。
要点
- 孤立性RBD是α-突触核蛋白病的早期阶段,异常沉积早于运动症状数十年。
- 可靠生物标志物有助于预测向临床α-突触核蛋白病的转化。
- 疾病进展和亚型标志物对监测治疗反应和预测亚型至关重要。
核心结论
- 孤立性RBD患者常处于α-突触核蛋白病早期,开发生物标志物预测转化、监测进展和亚型对临床与研究至关重要。
研究设计与样本
- 综述文章,未报告系统检索范围或样本量。
主要发现
- α-突触核蛋白异常沉积在神经退行性过程早期出现于中枢和外周神经系统,可能早于运动症状和认知下降数十年。
临床怎么用
- 生物标志物可用于预测孤立性RBD患者向临床α-突触核蛋白病的转化,并在疾病修饰治疗可用时监测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.
引用
- Miglis MG, Adler CH, Antelmi E, et al. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 2021. PMID: 34302789. doi:10.1016/S1474-4422(21)00176-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。